The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Multiple myeloma (MM) is a remarkable example of rapid bench-to-bedside translation in new drug development. The proteasome inhibitor bortezomib and immunomodulatory drug lenalidomide targeted MM cells in the bone marrow (BM) microenvironment to overcome conventional drug resistance in laboratory and animal models and were rapidly translated into clinical trials demonstrating their efficacy in patients with relapsed and then newly diagnosed MM, with a doubling of the median survival as a direct result. The future is even brighter. First, immune-based therapies are being developed (eg, elotuzumab monoclonal antibody [MoAb]; CD138DM immunotoxin; MM cell–dendritic cell vaccines; CD138, CS-1, and XBP-1 peptide vaccines; anti-17 MoAb; and other treatments to overcome causes of immune dysfunction). Second, promising next-generation agents target the MM cell in its microenvironment (eg, deubiquitinating enzyme inhibitors; chymotryptic [carfilzomib, Onyx 0912, MLN 9708] and broader [NPI-0052] proteasome inhibitors; immunoproteasome inhibitors; and pomalidamide). Moreover, agents targeting bone biology (eg, zoledronic acid, anti–DKK-1 MoAb, anti–B-cell activating factor MoAb and bortezomib, Btk inhibitor) show promise not only in preserving bone integrity but also against MM. Third, rationally based combination therapies, including bortezomib with Akt, mammalian target of rapamycin, or histone deacetylase inhibitors, are active even in bortezomib-refractory MM. Finally, genomics is currently being used in the definition of MM heterogeneity, new target discovery, and development of personalized therapy. Myeloma therefore represents a paradigm for targeting the tumor in its microenvironment, which has already markedly improved patient outcome in MM and has great potential in other hematologic malignancies and solid tumors as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932 · cited 2×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript bortezomib, for example, triggers MM cell cytotoxicity in the BM, whereas the anti-tumor activity of dexamethasone is attenuated.21 At both the gene transcript and proteasome activity levels, the ubiquitin proteasome cascade is upregulated…”
BackgroundSelf-citationRichardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Self-citationRichardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citationChauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694
Self-citationRichardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citationPalumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8216 · Cited by 423
Cited by
Kumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2014) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,369
Dou, Q., & Zonder, J. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140804154511 · Cited by 275
The Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272
Association of response endpoints with survival outcomes in multiple myeloma
Lonial, S., & Anderson, K. C. (2014) · Leukemia · doi:10.1038/leu.2013.220 · Cited by 162
Self-citationDas, D. S., Ray, A., Song, Y., Richardson, P., Trikha, M., Chauhan, D., & Anderson, K. C. (2015) · British Journal of Haematology · doi:10.1111/bjh.13780 · Cited by 49
Self-citationMultiple Myeloma: From Front-Line to Relapsed Therapies
Moreau, P., & Touzeau, C. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e504 · Cited by 48
Hirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01909-7 · Cited by 25
Metadata
- Authors
- Anderson, K. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-02-01
- Volume
- 30
- Issue
- 4
- Pages
- 445-452
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2161160225
- Cited by
- 129
- References
- 14
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.